Repligen Corporation Stock News

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

WALTHAM, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presentin

Repligen's (RGEN) second-quarter earnings and revenues beat their respective Zacks Consensus Estimate. Chromatography and process analytics businesses are the key growth drivers in the quarter.

Repligen Corporation (NASDAQ:RGEN ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Ex

Repligen (RGEN) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.91 per share a year ago.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Repligen (RGEN). But which of these two stocks presents investors wi

Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 million in FY22, largely due to their single-use produ

Repligen Corporation is facing tougher comparables with the pandemic-related revenue contribution vanishing. This is expected, but the softer organic growth in the base business is disappointing. With

Repligen's (RGEN) first-quarter earnings and revenues beat estimates.

Repligen (RGEN) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.92 per share a year ago.

Repligen is set to release its first-quarter earnings next Tuesday. Demand for its COVID-related products is declining, and investors appear to be bracing for the company to miss Wall Street's consens

Webcast and Conference Call to Be Held Tuesday, May 2, 2023, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, May 2, 2023, at 8:30 a.m. ET

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virt

Repligen's exclusive partnerships with companies such as DRS Daylight Solutions and Purolite give it a competitive edge in the industry. The company's diverse product line includes pre-packed columns,